Summary
CBL is a photodegradation product of cannabichromene (CBC), occurring naturally in aged or UV-exposed Cannabis. Human pharmacology remains almost completely unstudied; however, recent 2025 research revealed CBL has high affinity for the 5-HT1A serotonin receptor, acting as a potent positive allosteric modulator at low concentrations. A 1976 study in rabbits showed convulsions and death at 8 mg/kg, though this limited two-animal study offers minimal guidance for human safety. Commercial CBL products are not currently available. People subject to workplace or legal drug testing should note that CBL may be reported generically as a cannabinoid, though it is not scheduled under UN drug conventions.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | Nodata | - | - | - |
| Sublingual | Nodata | - | - | - |
| Inhaled | Nodata | - | - | - |
Light
Common
Strong
Heavy
Tolerance
Build-up
develops over weeks of regular use via CB1 receptor downregulation
Reset
2–4 weeks for most users; heavy users may need longer